Sanofi pulls Lyxumia in Germany

Sanofi (Euronext:SAN; NYSE:SNY) said it will no longer market Type II diabetes drug Lyxumia lixisenatide in Germany after failing to agree on a price with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). Sanofi said it may reexamine the move after a price for the glucagon-like peptide-1 receptor ( GLP-1R) agonist is determined through independent arbitration. In September, Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Lyxumia has "no additional benefit" over comparators (see BioCentury Extra, Sept. 5, 2013). ...